B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104
BridgeBio Pharma
BridgeBio Pharma BBIO | 0.00 |
B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:
BBIO) with a Buy and raises the price target from $101 to $104.
